Download App

Log in to access Online Inquiry
Company Overview More
Hainan Puli Pharmaceutical Co., Ltd., founded in 1992, is a high-tech enterprise specializing in the research, development, production and sales of chemical pharmaceutical preparations. The company is a high-tech enterprise specializing in drug research and development, registration, production and sales. The company mainly sells prescription drugs, covering anti-allergic drugs, non-steroidal analgesic and anti-inflammatory drugs, antibiotics, digestive drugs and other fields. Enterprise Honor: the project of "Development and production Transformation of Diclofenac Sodium Enteric-coated sustained release capsule" won the second prize of science and technology of Hainan Province, and the project of "Development and industrialization of desloratadine dry suspension" won the third prize of Science and Technology of Hainan Province. "Fu Biding (desloratadine dry suspension)" was rated as an excellent product of Hainan pharmaceutical industry by Hainan Pharmaceutical Industry Association. Desloratadine dispersible tablets and desloratadine dry suspension won the list of hospital terminals and grass-roots terminals in 2016 China Pharmaceutical Brand list (anti-allergic drug category) at the 28th National Pharmaceutical Economic Information Conference.
CEO: --
Market: --
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

300630 Hainan Poly Pharm
27.300+0.380+1.41%
YOY
Do not show
Hide blank lines
(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30(Q6)2021/06/30
Assets
Current assets
Money funds
-45.11% 470.6M 24% 442.26M 153.83% 624.77M 125.34% 738.71M
Transactional financial assets
0% 550.35K 12719.11% 70.55M -99.76% 550.35K -99.76% 550.35K
Notes receivable and accounts receivable
46.93% 870.21M 46.37% 875.76M 53.94% 758.3M 57.53% 663.35M
-Accounts receivable
46.93% 870.21M 46.37% 875.76M 53.94% 758.3M 57.53% 663.35M
Other receivables (including interest and dividends)
153.64% 12.79M 337.09% 13.88M -21.28% 7.94M -36.23% 6.51M
-Other receivable
-- -- -- -- -- -- -36.23% 6.51M
Advance payment
397.72% 191.77M 586.68% 254.51M -5.48% 61.04M 259.94% 82.26M
Inventories
178.12% 317.58M 178.64% 262.17M 111.7% 281.05M 98.26% 234.79M
Receivable financing
4.66% 73.69M -18.28% 71.63M 1129.51% 109.1M 264.31% 63.53M
Other current assets
-18.52% 23.7M -38.01% 34.26M -61.25% 29.08M 107.31% 85.15M
Total current assets
14.84% 1.96B 64.26% 2.03B 48.55% 1.87B 57.69% 1.87B
Non Current assets
Investment real estate
-9.99% 23.59M -7.99% 24.12M -7.83% 24.64M -7.68% 25.16M
Fixed assets
-- -- -- -- -- -- 25.91% 559.94M
Fixed assets liquidation
-- -- -- -- -- -- -- 0
Constru in process
-- -- -- -- -- -- 72.02% 1.46B
Construction materials
-- -- -- -- -- -- -- 0
Intangible assets
33.92% 153.58M 37.85% 129.92M 14.54% 109.55M 15.22% 111.66M
Development expenditure
43.57% 143.61M 15.3% 139.76M 202.28% 109.49M 196.74% 104.16M
Deferred tax assets
0% 20.93M 45.46% 32.46M 148.84% 23.91M 106.69% 21.76M
Usufruct assets
-- 6.31M -- 6.81M -- -- -- --
Other non current assets
-- -- -- 102.32M -- -- -- --
Total non current assets
30.61% 2.98B 44.65% 2.64B 69.65% 2.58B 55.99% 2.28B
Total assets
23.86% 4.94B 52.56% 4.66B 60.1% 4.46B 56.75% 4.15B
Liabilities
Current liabilities
Short term loan
275.8% 466.07M 104.46% 347.11M -7.37% 315.65M -46.61% 167.08M
Notes payable and accounts payable
22.86% 448.2M 54.64% 432.97M 181.54% 399.22M 131.05% 367.72M
-Notes payable
193.87% 283.91M 114.11% 204.71M -- 139.71M -- 115.32M
-Accounts payable
-38.74% 164.29M 23.81% 228.27M 83.01% 259.51M 58.59% 252.4M
Contract liabilities
27.43% 46.59M 59.25% 40.64M -- 18.03M -20.39% 22.02M
Salaries payable
35.67% 7.96M 58.34% 14.45M 69.26% 7.72M 38.46% 6.76M
Taxs payable
-25.61% 34.45M 26.07% 130.78M 117.98% 116.83M 28.73% 72.12M
Other payable (including interest and dividends)
-54.8% 35.06M -24.34% 59.76M 372.98% 67.22M 116.91% 163.21M
-Interest payable
-- -- -- -- -- -- -- 1.08M
-Dividend payable
-- -- -- -- -- -- 35.2% 81.72M
-Other payable
-- -- -- -- -- -- 443.47% 80.41M
Non current liabilities due within one year
0% 1.12M -24.13% 3.13M -64.18% 1.12M -64.13% 1.12M
Other current liabilities
-- -- 226.53% 10.83M -- 2.34M -- 2.86M
Total current liabilities
57.6% 1.04B 54.13% 1.04B 55.57% 928.14M 25.64% 802.9M
Current liabilities
Long term loan
86.47% 298.52M -5.87% 183.37M 10.87% 154.02M 15.42% 160.35M
Bonds payable
24.12% 755.27M -- 742.48M -- 631.15M -- 621.03M
Long term account payable
-- -- -- -- -- -- -5.51% 12M
Specific account payable
-- -- -- -- -- -- 0% 7.87M
Deferred tax liabilities
0% 47.25M 38.05% 65.22M 98.93% 47.25M 119.23% 47.99M
Long term deferred income
-6.1% 74.92M -5.96% 75.57M 71.29% 78.27M 70.64% 78.97M
Lease liabilities
-- 6.4M -- 6.29M -- -- -- --
Total non current liabilities
30.01% 1.19B 215.76% 1.08B 301.22% 918.56M 307.71% 928.21M
Exceptional items of total current liabilities
-- 0 -- 0 -- 0 -- 0
Total liabilities
41.56% 2.23B 108.54% 2.12B 123.69% 1.85B 99.74% 1.73B
Shareholders equity
Paid-in capital
-0.01% 436.98M -0% 436.98M -0% 436.98M 53.9% 437.03M
Other equity instruments
-38.97% 139.99M -- 139.99M -- 229.37M -- 229.37M
Capital reserve funds
2.54% 682.66M 1.8% 676.75M 3.4% 680.93M -11.61% 676.62M
Surplus reserve funds
35.6% 154.05M 35.6% 154.05M 41.68% 113.6M 41.68% 113.6M
Retained profit
30.88% 1.33B 33.85% 1.16B 50.87% 1.18B 54.86% 1.01B
Less:Treasury stock
-31.8% 31.42M -31.8% 31.42M -- 31.42M -- 46.08M
Specific reserves
-- 1.43M -- 1.13M -- -- -- --
Shareholders equity without minority interests
12.3% 2.71B 24.65% 2.54B 33.28% 2.61B 35.87% 2.42B
Total shareholder equity
12.3% 2.71B 24.65% 2.54B 33.28% 2.61B 35.87% 2.42B
Total liabilityies and equity
23.86% 4.94B 52.56% 4.66B 60.1% 4.46B 56.75% 4.15B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
--Unqualified opinion----
Auditor
--Tianjian Accounting firm (Special General Partnership)----

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%